anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hybridization coupled to polyploidy, or allopolyploidy, has dramatically shaped the evolution of flowering plants, teleost fishes, and other lineages. Studies of recently formed allopolyploid plants have shown that the two subgenomes that merged to form that new allopolyploid do not generally express their genes equally. Instead, one of the two subgenomes expresses its paralogs more highly on average. Meanwhile, older allopolyploidy events tend to show biases in duplicate losses, with one of the two subgenomes retaining more genes than the other. Since reduced expression is a pathway to duplicate loss, understanding the origins of expression biases may help explain the origins of biased losses. Because we expect gene expression levels to experience stabilizing selection, our conceptual frameworks for how allopolyploid organisms form tend to assume that the new allopolyploid will show balanced expression between its subgenomes. It is then necessary to invoke phenomena such as differences in the suppression of repetitive elements to explain the observed expression imbalances. Here we show that, even for phenotypically identical diploid progenitors, the inherent kinetics of gene expression give rise to biases between the expression levels of the progenitor genes in the hybrid. Some of these biases are expected to be gene-specific and not give rise to global differences in progenitor gene expression. However, particularly in the case of allopolyploids formed from progenitors with different genome sizes, global expression biases favoring one subgenome are expected immediately on formation. Hence, expression biases are arguably the expectation upon allopolyploid formation rather than a phenomenon needing explanation. In the future, a deeper understanding of the kinetics of allopolyploidy may allow us to better understand both biases in duplicate losses and hybrid vigor.
A method for constructing stable bioactive fusion proteins of the difficult to express tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is described. Single trimers of these proteins lack the full stimulatory efficacy of the natural membrane forms of these proteins in many cases. The multimeric nature of these soluble fusion proteins enables them to engage multiple receptors on the responding cells, thereby, mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This property may be especially useful when these proteins are injected locally as a vaccine adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition, these and other TNFSF-collectin fusion proteins present new possibilities for the expression of highly active, multimeric, soluble TNFSF members.
Inhibitors of AMPA-type glutamate ion channels are useful as biochemical probes for structure-function studies and as drug candidates for a number of neurological disorders and diseases. Disclosed herein is the identification of an RNA inhibitor or aptamer by an in vitro evolution approach and characterization of its mechanism of inhibition on the sites of interaction by equilibrium binding and on the receptor channel-opening rate by a laser-pulse photolysis technique. The aptamer of the invention is a noncompetitive inhibitor of AMPA-type glutamate ion channels, one that selectively inhibits the GluA2Q flip  AMPA receptor subunit without any effect on other AMPA receptor subunits or on kainate or NMDA receptors. Furthermore, the aptamer preferentially inhibits the closed-channel state of GluA2Q flip  with a KI = 1.5 µM or by ~15-fold over the open-channel state. The potency and selectivity of this aptamer rival those of small molecule inhibitors. Together, these properties make the aptamers of the present invention promising water-soluble, highly potent, GluA2 subunit-selective drugs.
After the group allocation is determined, patients in the experimental group will undergo CA-IX PET/CT scans. Subsequently, they will commence taking metformin at a dose of 850 mg per tablet, once daily, for three consecutive days. One week later, a second CA-IX PET/CT scan will be performed. Following this, synchronous chemoradiotherapy will be initiated, with patients taking metformin twice daily during the course of radiotherapy, at a dosage of one tablet per administration.
Cardiovascular diseases remain the major cause of mortality and morbidity in industrialised countries. Their prevalence increases steeply as consequence of the aging of the population in these countries. Curiously, cardiovascular and neurodegenerative diseases share common aging pathological pathways involving abnormal accumulation of insoluble amyloid proteins in the extracellular matrix disrupting normal organ function. Whereas neurological amyloid diseases has been considerably investigated, little attention has been paid to the aggregation of amyloid proteins in cardiovascular diseases. Post-mortem studies have identified cardiac wild-type transthyretin amyloidosis deposition in 25% of individuals over the age of 80 years leading to the concept of "senile cardiac amyloidosis" (CA) (Cornwell, Am j Med 1984; Pitkanen, Am J Pathol 1984). The cause of this deposition is not yet known but might be related primarily to aging process and enhanced by cardiac mechanical stress (overload), hypoxia, oxidative stress and inflammation. Since patients with transthyretin CA develop severe heart failure with poor prognosis, it is crucial to identify them especially among population at risk such those with aortic stenosis (AS). Indeed this common valvular heart disease affects mainly senescent subjects and combines so the adverse effects on myocardial function of both pressure overload and myocardial aging.

Interestingly, some elderly patients with severe AS exhibit similar echocardiographic and cardiac MRI patterns as those reported in CA including increased cardiac wall thickness and progressive left ventricular dysfunction starting with alteration of basal LV-2D strain. They also exhibit increased late gadolinium enhancement (LGE) at cardiac MRI. This has been interpreted as related to interstitial myocardial "fibrosis" and has been correlated with poor prognosis after aortic valve replacement i.e.; high mortality, persistence of heart failure symptoms and LV dysfunction (Weidemann Circ 2009; Dweck, JACC 2011; Hermann JACC 2011). However none of these patients have benefited from a detailed histology analysis with aiming at identifying amyloid deposits. The investigators have recently found similar clinical observations in the investigators AS cohort. Using specific staining, the investigators were able to unmask the association of severe AS and CA in these patients. These preliminary findings raise the question of a potential pathophysiological link between CA and AS and might explain why some patients with AS may not benefit from cardiac surgery.
The present invention relates to a gout capsule for treating gout and nourishing kidney, which is processed according to a certain proportion of weight of the following raw materials: shengchuanwu, maqianzi, schisandra, grassleaved sweetflag, raw kusnezoff monkshood root, Hibiscus schizopetalus, mastic, radix achyranthis bidentatae, Chinese caterpillar fungus, radix notoginseng, muskiness, pangolin and an asarum. The present invention has the functions of conditioning liver and kidney, balancing the proportion of acid and alkali, promoting metabolism, enhancing immunity, relieving rigidity of muscles and promoting blood circulation, dissipating blood stasis and alleviating pain. Clinical patients prove that the treatment period is short and the effect is immediate. In acute gout, patients can relieve the sufferings within 3 to 5 days by taking the capsule and fundamentally cure gout and recover within 100 days. After healing, the present invention has the advantages of no repeated attack, no toxic side effects as well as health protection. 20 days after taking the medicine, patients are unnecessary to avoid certain food.
To identify preoperative predictive factors for final ureteral section invasion after radical cystotomie (RC) and to validate significant factors on an external independent cohort. Pathological evaluation was performed by 2 well-trained uropathologists in each center (Y.A. and C.C). The investigators retrospectively reviewed data of all consecutive RC performed for bladder cancer in 2 high-volume institutions. Clinical, pathological, and follow-up data were collected prospectively and reviewed retrospectively. Pathological evaluation was performed by 2 well-trained uropathologists in each center. Logistic regression analyses were performed to identify predictive factors for final ureteral sections involvement. Significant factors in cohort A were validated in cohort B. Receiver operating curve and area under curve were modeled to evaluate predictive accuracy of the markers
1357023 Precipitating bacteria; vaccines SOUTH AFRICAN INVENTIONS DEVELOPMENT CORP 20 Sept 1971 [18 Sept 1970 (2)] 43808/71 Heading A5B Bacteria are precipitated from aqueous media by addition thereto of a linear, filamentary, non-charged polymer which, in the quantity used (usually up to 6% by volume), should not significantly raise the viscosity. Suitable polymers are: polyalkylene glycols (especially PEG of MW 4000-9000), dextran, polyvinyl alcohol, polyvinyl pyrrolidone and nonylphenol ethoxylate. The procedure may be used in preparing vaccines, specific examples relating to the preparation of vaccines against pulpy kidney disease (containing Cl. Welchii type D), fowl typhoid (containing Salmonella gallinarum), live Brucella abortus vaccine, a multiple strain vaccine containing 8 strains of Pasteurella multocida and a Black Quarter Disease vaccine (containing Cl. Chauvoei). In each case, PEG is used to precipitate the bacteria.
The present invention relates to a preparation technology and a production method for an integrated new formulation of a cinnamon twig plus genseng decoction, wherein the raw materials of active ingredients comprise: 9 parts by weight of cinnamon twig, 12 parts by weight of white peony root, 6 parts by weight of honey-fried licorice root, 6 parts by weight of ginseng, 12 parts by weight of ginger, and 4 parts by weight of Chinese-date. The production process of the integrated new formulation of cinnamon twig plus genseng decoction comprises the following steps of: supersonic air-jet crushing, alcohol-water extraction, ultrasonic crushing extraction, water decocting concentration, supersonic spray drying, nanometer grinding, high pressure homogenization, nano particle preparation and the like. According to the invention, the advantages, such as multi-synergism, multi-target, embodied by a nano-carrier coupling technique, are focused to be taken of. After the integrated new formulation of cinnamon twig plus genseng decoction is subjected to scale production, the production cost can be greatly reduced, the quality of products is greatly improved and the targeting property and the sustained and controlled release performance of the medicament are enhanced. The internal and external administration of the integrated new formulation of cinnamon twig plus genseng decoction can be realized simultaneously, and can be respectively taken in four time slices according to midnight-noon ebb-flow and qi and blood flowing rule of a human body. The integrated new formulation of cinnamon twig plus genseng decoction can be further prepared into films and transdermal agents which are respectively stuck to different parts of a human body according to the midnight-noon ebb-flow and qi and blood flowing rule of the human body and can be directly absorbed through skin.
FIELD: medicine. SUBSTANCE: tissular transplantable composition has submucous tela tunic of small intestine segment taken from a warm-blooded vertebrate. The submucous tela tunic is separated as a layer from tunica muscularis and at least from the cavitary part of mucous membrane. The tissular transplantable composition has excellent mechanical properties without being allergic and thrombogenic when used as vascular autograft, allograft or heterograft. EFFECT: higher effectiveness of vasoplastic operations, prevented postoperative complications. 3 cl, 1 dwg
Dumping syndrome (DS) is a collection of gastrointestinal (GI) and vasomotor symptoms arising postprandially because of prompt gastric emptying. This can develop due to any changes in gastric anatomy or innervation during esophageal, gastric, or bariatric surgery. Due to the increase in the number of bariatric operations and innovative surgeries performed internationally, bariatric surgery has emerged as the most common cause of this disease entity. 25-50% of all gastric surgery patients experience dumping symptoms after their procedures. Patients who have had Roux-en-Y gastric bypass (RYGB) are at an extremely high risk (up to 40%) of developing dumping syndrome postoperatively. The goal of this review is to provide an insightful evaluation of the most recent literature on the overlooked scientific and clinical elements of dumping syndrome, such as diagnostic aspects, pathogenesis, terminology, and management. More research is needed to establish guidelines and terms used to properly document and manage dumping syndrome.
Hypoactive sexual desire dysfunction (HSDD) is prevalent among women. This retrospective cohort study aimed to verify the results of the strategies used by Gynecologists and Obstetricians (Ob-gyn) residents in the management of female HSDD. For this, we conducted a data collection of patient medical records of women with HSDD from the Human Sexuality Studies outpatient clinic of the Human Reproduction Center, Department of Gynecology and Obstetrics of FMRP-USP, from 2005 to 2019. Among the 437 women included, 361 (82.6%) answered the question concerning the effect of the protocol to which they were submitted, whereas 234 (64.8%) reported improvements in sexual desire. The univariate model showed that patients without chronic pelvic pain were 19.0% less likely to report improvements in HSDD than those with chronic pelvic pain (p = 0.03). Patients without depression and without orgasmic dysfunction were, respectively 32% and 23% more likely to show improvements in their HSDD than those who had depression or orgasmic dysfunction (respectively p = 0.001, p = 0.008). However, the multivariate model did not identify any associations. The assistance regarding HSDD by the Ob-gyn resident in training to deal with female sexual complaints may be effective in improving sexual complaints.
During the entire 18 months of the protocol, these subjects will receive immediate release prednisone as a morning dose. All observations and measurements are performed the same as the other study groups.
Novel recombinant constructs bearing immunogenic genes derived from RNA viruses are disclosed. The constructs contain gene sequences derived from immunogenic viral proteins (termed "backbone proteins" herein) which have hypervariable regions. The hypervariable regions are replaced, in whole or part, with consensus sequences or with corresponding hypervariable gene sequences from viral isolates other than the parent isolate. The constructs are conveniently engineered so that the replacement sequence is flanked with unique restriction sites. In this way, a variety of immunogenic sequences, e.g., from related strains of viruses, can be easily inserted into, and excised from, the construct. The proteins derived from the constructs can be used in vaccine compositions and diagnostics for the prevention and diagnosis, respectively, of the virus in question.
This is a prospective single site Type 1 hybrid effectiveness-implementation parallel mixed methods (QUANT + qual) quasi-experimental study. This study design involves simultaneous collection and analysis of quantitative and qualitative data, giving priority weight to the quantitative data to evaluate program referrals, outcomes, and program fidelity, while qualitative data will evaluate process through detailed descriptions of perspectives of barriers and facilitators faced by health care providers in implementing the THRIVE intervention. Qualitative interviews will also assess stakeholder perspectives of the value of the intervention in addressing health inequities among Medicaid insured individuals cared for in the acute and home care settings. Nesting the qualitative interview within a single-site randomized trial of a the THRIVE intervention will allow us to determine whether the intervention improved primary outcomes (referrals to homecare, 30-day readmission, ED utilization, connection to PCP) and to identify professional and organizational barriers to implementation. Combining these insights with that of effectiveness outcome date will allow consideration for meaningful contextual factors that are viewed as critical to the implementation of THRIVE and subsequent outcomes. Our stepped wedge design with include a randomized roll-out to case managers at Pennsylvania Hospital and the study will be carried out over 18 months. To begin, 5 case managers will be randomized to receive training on the THRIVE clinical pathway. Following training they will be invited to begin offering referrals to the THRIVE clinical pathway. After 2 months the remaining 4 case managers will be trained on the THRIVE intervention and will be able to begin submitting referrals.
The present disclosure provides feed additive compositions and related methods for the treatment and prevention of  Clostridium  associate disease. The feed additive compositions herein can include a microbial fermentate product. The microbial fermentate product can be present in the feed additive composition in an amount effective to produce an inhibitory effect against  Clostridium  bacteria in an animal. The  Clostridium  bacteria can include several species of  Clostridium  bacteria, including  Clostridium perfringens . The inhibitory effect can include a direct or indirect inhibition of growth of  Clostridium  bacteria. The inhibitory effect against  Clostridium  bacteria can result in one or more beneficial effects for the animal. Other aspects are also included herein.
Once proper placement of the LMA was achieved, surfactant (Curosurf®, 2.5 ml/kg, Chiesi USA, Inc., Cary, NC) was administered. The LMA cuff was then deflated, LMA removed and the infant placed back on nasal CPAP 6 cm H2O.
The invention relates to a lubricating nourishing agent containing egg liquid and glycerin, which pertains to the field of cosmetics with the function of health care. The invention is characterized by adding one or a plurality of common drug accessories, extracts of Chinese herbal medicine, chemical active ingredient in addition to egg liquid and glycerin. The lubricating nourishing agent can be used for relieving vaginal dryness due to lacking vaginal secretions and relieving dyspareunia; the lubricating nourishing agent can also be used for skin cosmetic, such as human faces or hands. In addition, the lubricating nourishing agent can also be used for adjuvant therapy of vaginitis, pruritus vulvue and the like by adding extracts of Chinese herbal medicine and chemical active ingredient. Due to age or diseases, women, especially elderly or middle-aged women tend to be suffered from vaginal dryness due to lacking vaginal secretions, which has impact on sex life or even leads to marital disruption. The lubricating nourishing agent has both good effect on curing vaginal dryness for women and skin care effects.
Isosorbide dinitrate (ISDN) is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate, an organic nitrate whose structural formula is

and whose molecular weight is 236.14. The organic nitrates are vasodilators, active on both arteries and veins.

Isosorbide dinitrate is a white, crystalline powder compound which is stable in air and in solution, has a melting point of 69°C to 72°C and optically active. Isosorbide dinitrate is very soluble in acetone, sparingy soluble in alcohol and very slightly soluble in water.

Each Isosorbide dinitrate tablet contains 20 mg of isosorbide dinitrate. The inactive ingredients in each tablet are microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The 20 mg dosage strength also contains anhydrous lactose and sodium starch glycolate Type A. Additionally 20mg contains FD & C Blue 1 Al lake and D & C Yellow 10 Al lake.

FDA approved dissolution test specifications differ from USP.
The invention discloses application of Houttuynoid D in preparing a hepatic fibrosis treating medicine. Pharmacological tests prove that Houttuynoid D can obviously inhibit the occurrence and the development of hepatic fibrosis, and can be used for preparing a medicine for preventing hepatic fibrosis and a medicine for preventing and treating cirrhosis. The application of Houttuynoid D in preparing medicine for inhibiting liver fibroblast proliferation, which is provided by the invention, is disclosed for the first time. The skeleton type belongs to brand-new skeleton type, and the inhibitingactivity of Houttuynoid D to liver fibroblast proliferation is extremely strong, so that no possibility for providing any prompt by other compounds exists. Houttuynoid D has outstanding actual characteristics. Meanwhile, Houttuynoid D has outstanding progress when being used for inhibiting liver fibroblast.